Day: July 25, 2024

WARSAW, Ind., July 25, 2024 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported net income of $22.5 million for the three months ended June 30, 2024, which represents an increase of $7.9 million, or 54%, compared with net income of $14.6 million for the three months ended June 30, 2023. Diluted earnings per share were $0.87 for the second quarter of 2024 and increased 53% compared to $0.57 for the second quarter of 2023. On a linked quarter basis, net income decreased $852,000, or 4%, from first quarter 2024 net income of $23.4 million and diluted earnings per share decreased $0.04 or 4% from $0.91 at March 31, 2024. Pretax pre-provision earnings, which is a non-GAAP measure, were $35.4 million for the three months ended June 30, 2024, an increase of $18.1...

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — Perella Weinberg Partners (NASDAQ:PWP), a leading global independent advisory firm, today announced the promotion of four Managing Directors to Partners of the Firm.William Glass – Healthcare, New York Alexandra Gottschalk – Chief Financial Officer, Houston Sam Tanzer – Financing & Capital Solutions, New York Rebekah Weissburg – Chief Human Resources Officer, New York“We are pleased to announce the promotion of Will, Alex, Sam and Rebekah to Partner. Each has made meaningful contributions to our business and culture, and each has had an unwavering commitment to upholding our core values of trust, integrity and teamwork,” said Andrew Bednar, Chief Executive Officer. “Our new Partners will continue to lead our talented teams in putting clients first, enhancing our franchise, and...

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the second quarter 2024 of $70.4 million, or $0.13 per diluted common share, as compared to the first quarter 2024 net income of $96.3 million, or $0.18 per diluted common share, and net income of $139.1 million, or $0.27 per diluted common share, for the second quarter 2023. Excluding all non-core income and charges, our adjusted net income (a non-GAAP measure) was $71.6 million, or $0.13 per diluted common share, for the second quarter 2024, $99.4 million, or $0.19 per diluted common share, for the first quarter 2024, and $147.1 million, or $0.28 per diluted common share, for the second quarter 2023. See further details below, including a reconciliation of our non-GAAP adjusted...

AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s DiseaseTreatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partnerLausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The recently initiated Phase 2b clinical trial ReTain is currently recruiting participants with preclinical Alzheimer’s disease, where individuals have yet to show...

Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology Biomarker discovery market estimated by third party research to be $51.5 billion in 2024 PITTSBURGH, July 25, 2024 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it is expanding its AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology. Predictive Oncology’s biomarker discovery initiative stems, in part, from results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital, which were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. In that study, Predictive...

• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a novel modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 1 million people in the United States. “Currently, there are two FDA approved anti-complement therapies for GA, which targets only one pathway for a disease that has a multifactorial and complex etiology,” said Majda Hadziahmetovic, MD, Associate Professor of Ophthalmology, Vitreoretinal...

Second quarter 2024 aircraft deliveries reached 39 units and total revenues climbed to $2.2 billion, with Services contributing $507 million, reflecting year-over-year growth of 34%, 32% and 18%, respectively. Adjusted EBITDA(1) of $335 million for the second quarter was up 22% year-over-year, and adjusted EBITDA margin(2) was 15.2%. Reported EBIT for the second quarter was $191 million. Adjusted EPS(2) was positive at $1.04 for the second quarter, with diluted EPS(3) at $0.12. Free cash flow usage(1) of $68 million represented a $154 million improvement compared to the same quarter of 2023. Reported cash flow usage from operating activities and net additions to PP&E and intangible assets were $31 million and $37 million, respectively.​ Backlog(4) as at June 30, 2024 was $14.9 billion on unit book-to-bill(5) of 1.0, reflecting consistent...